{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:34:20Z","timestamp":1767591260354,"version":"3.48.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Pancreatic neuroendocrine tumors (pNETs) can change their hormonal profile over time, leading to new clinical syndromes that significantly impact prognosis and management. We report the case of a patient with a metastatic glucagon-secreting pNET who, after 14 years of disease and multiple treatment lines, developed insulin hypersecretion and severe, treatment-refractory hypoglycemia. Despite several strategies, including diazoxide, somatostatin analogues, glucocorticoids, everolimus, peptide receptor radionuclide therapy, and continuous glucose and glucagon infusions, glycemic control was not achieved, and the patient ultimately died from treatment complications. This case highlights the clinical challenges of managing metachronous hormonal syndromes and the importance of long-term endocrine follow-up in pNET patients. It also emphasizes the limitations of current therapeutic strategies and the urgent need for new treatment options, including alpha-emitting radiopharmaceuticals, which may offer improved disease and symptom control in advanced, insulin-secreting pNETs.<\/jats:p>","DOI":"10.3389\/fendo.2025.1729451","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:29:19Z","timestamp":1767590959000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Shift in secretory profile of a pNET: from indolent glucagonoma to aggressive insulinoma \u2013 a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Sara","family":"Gil dos Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Calheiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Paula","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Souteiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e13318","DOI":"10.1111\/jne.13318","article-title":"European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes","volume":"35","author":"Hofland","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coemr.2021.04.007","article-title":"Functioning and nonfunctioning pNENs","volume":"18","author":"Daskalakis","year":"2021","journal-title":"Curr Opin Endocrine Metab Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13345","article-title":"Synchronous insulinoma and glucagonoma: A review of the literature","volume":"37","author":"Damaskos","year":"2023","journal-title":"In Vivo"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i16.5124","article-title":"Malignant insulinoma: Can we predict the long-term outcomes","volume":"10","author":"Cigrovski Berkovic","year":"2022","journal-title":"World J Clin cases"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2436","article-title":"Multiple and secondary hormone secretion in patients with metastatic pancreatic neuroendocrine tumours","volume":"101","author":"Crona","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","article-title":"Insulinoma","volume-title":"Endotext","author":"de Herder","year":"2023"},{"key":"B7","volume-title":"Glucagon & Glucagonoma syndrome","author":"de Herder","year":"2023"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-20-0473","article-title":"Changing biological behaviour of NETs during the evolution of the disease: progress on progression","volume":"28","author":"Alexandraki","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad641","article-title":"Approach to the patient: insulinoma","volume":"109","author":"Hofland","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ebb168","article-title":"NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas","volume":"39","author":"Kulke","year":"2010","journal-title":"Pancreas"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.860614","article-title":"Pasireotide for refractory hypoglycemia in Malignant insulinoma- case report and review of the literature","volume":"13","author":"Oziel-Taieb","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2020.08.003","article-title":"Comparison of benign and Malignant insulinoma","volume":"221","author":"Sada","year":"2021","journal-title":"Am J Surg"},{"key":"B13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.pan.2018.01.009","article-title":"Insulinoma: A retrospective study analyzing the differences between benign and Malignant tumors","volume":"18","author":"C\u00e2mara-de-Souza","year":"2018","journal-title":"Pancreatology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v5.i6.847","article-title":"Transdifferentiation of pancreatic \u03b1-cells into insulin-secreting cells: From experimental models to underlying mechanisms","volume":"5","author":"Lu","year":"2014","journal-title":"World J Diabetes"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nature13633","article-title":"Diabetes recovery by age-dependent conversion of pancreatic \u03b4-cells into insulin producers","volume":"514","author":"Chera","year":"2014","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI66514","article-title":"Epigenomic plasticity enables human pancreatic \u03b1 to \u03b2 cell reprogramming","volume":"123","author":"Bramswig","year":"2013","journal-title":"J Clin Invest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2132","article-title":"Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study","volume":"162","author":"de Mestier","year":"2015","journal-title":"Ann Intern Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0203","article-title":"Factors associated with grade progression in pancreatic neuroendocrine tumors","volume":"32","author":"Wang","year":"2025","journal-title":"Endocr Relat Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02540-w","article-title":"Distinctive features of pancreatic neuroendocrine neoplasms exhibiting an increment in proliferative activity during the course of the disease","volume":"72","author":"Alexandraki","year":"2021","journal-title":"Endocrine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/jne.70040","article-title":"The impact of re-characterizing metastatic pancreatic neuroendocrine tumors: A prospective study","volume":"37","author":"Mollazadegan","year":"2025","journal-title":"J Neuroendocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000002171","article-title":"Analysis of clinical characteristics and survival in patients with functional neuroendocrine tumors of gastrointestinal origin","volume":"51","author":"Kaur","year":"2022","journal-title":"Pancreas"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2019.02.011","article-title":"Distinct clinicopathological and prognostic features of insulinoma with synchronous distant metastasis","volume":"19","author":"Gao","year":"2019","journal-title":"Pancreatology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-214702","article-title":"Hypoglycaemia due to insulin secretion from metastatic glucagonoma","volume":"2004","author":"Sankhla K","year":"2004","journal-title":"Soc Endocrinol BES"},{"key":"B24","doi-asserted-by":"publisher","first-page":"bvaa171","DOI":"10.1210\/jendso\/bvaa171","article-title":"Pasireotide: A novel treatment for tumor-induced hypoglycemia due to insulinoma and non-islet cell tumor hypoglycemia","volume":"5","author":"Siddiqui","year":"2021","journal-title":"J Endocr Soc"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/children10010005","article-title":"Diazoxide for neonatal hyperinsulinemic hypoglycemia and pulmonary hypertension","volume":"10","author":"Newman-Lindsay","year":"2022","journal-title":"Children (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13528","article-title":"Multidisciplinary management of refractory insulinomas","volume":"88","author":"Brown","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1159\/000508996","article-title":"Successful long-term medical management of unresectable insulinomas","volume":"13","author":"Spiro","year":"2020","journal-title":"Case Rep Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13343","article-title":"European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours","volume":"35","author":"Kos-Kud\u0142a","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","volume":"9","author":"Wolin","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5650","article-title":"Pasireotide use for the treatment of endogenous hyperinsulinemic hypoglycemia refractory to conventional medical therapy: A case report and review of the literature","volume":"10","author":"Husni","year":"2022","journal-title":"Clin Case Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025","volume":"48","year":"2024","journal-title":"Diabetes Care"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0222","article-title":"Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues","volume":"16","author":"Fiebrich","year":"2011","journal-title":"Oncologist"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyt193","article-title":"Everolimus dramatically improves glycemic control in unresectable metastatic insulinoma: a case report","volume":"44","author":"Asayama","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-1101","article-title":"Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia","volume":"168","author":"Bernard","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.0126-17","article-title":"The effect of everolimus on refractory hypoglycemia in a patient with inoperable metastatic insulinoma evaluated by continuous glucose monitoring","volume":"57","author":"Yanagiya","year":"2018","journal-title":"Intern Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-25-0091","article-title":"Comparative efficacy of systemic therapies in Malignant insulinoma","volume":"32","author":"Koch","year":"2025","journal-title":"Endocrine-Related Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-25-0018","article-title":"Peptide receptor radionuclide therapy in Malignant insulinoma","volume":"32","author":"Pattison","year":"2025","journal-title":"Endocr Relat Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-018-0911-3","article-title":"Peptide receptor radionuclide therapy with (177)Lu-DOTA-TATE as a promising treatment of Malignant insulinoma: a series of case reports and literature review","volume":"42","author":"Magalh\u00e3es","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030761","article-title":"Treatment of neuroendocrine neoplasms with radiolabeled peptides-where are we now","volume":"14","author":"Naik","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2022.12.007","article-title":"Molecular imaging theranostics of neuroendocrine tumors","volume":"53","author":"Fortunati","year":"2023","journal-title":"Semin Nucl Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with (225)Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to (177)Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety","volume":"47","author":"Ballal","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1210\/endrev\/bnae022","article-title":"Structure and function of somatostatin and its receptors in endocrinology","volume":"46","author":"Zhang","year":"2024","journal-title":"Endocrine Rev"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.186783","article-title":"Somatostatin receptor antagonists for imaging and therapy","volume":"58","author":"Fani","year":"2017","journal-title":"J Nucl Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0607761103","article-title":"Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors","volume":"103","author":"Ginj","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.258889","article-title":"First-in-humans study of the SSTR antagonist (177)Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms: dosimetry, safety, and efficacy","volume":"62","author":"Baum","year":"2021","journal-title":"J Nucl Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2307576","article-title":"Anti-insulin receptor antibody for Malignant insulinoma and refractory hypoglycemia","volume":"389","author":"Osataphan","year":"2023","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"luaf099","DOI":"10.1210\/jcemcr\/luaf099","article-title":"Alpelisib therapy in 2 patients with congenital hyperinsulinism","volume":"3","author":"Alburshad","year":"2025","journal-title":"JCEM Case Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2302935","article-title":"Alpelisib in intractable non-islet-cell tumor hypoglycemia","volume":"388","author":"Cahn","year":"2023","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab103","article-title":"PREVENT: A randomized, placebo-controlled crossover trial of avexitide for treatment of postbariatric hypoglycemia","volume":"106","author":"Craig","year":"2021","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1729451\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:29:20Z","timestamp":1767590960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1729451\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":49,"alternative-id":["10.3389\/fendo.2025.1729451"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1729451","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1729451"}}